Skip to content
Search
Please enter at least 3 characters.

Latest Stories

RPS launches new post-registration foundation pharmacist curriculum

The Royal Pharmaceutical Society (RPS) has launched its new post-registration foundation pharmacist curriculum to inform professional development training and pathways for early career pharmacists.

Considering the increased demand for pharmacists with enhanced clinical skills, the new curriculum articulates the knowledge, skills, behaviours and level of performance expected from post-registration foundation pharmacists working in patient-focused roles.


RPS has undertaken a significant programme of work in collaboration with a wide range of UK stakeholders to define this curriculum. The outcomes are based on the RPS Foundation Pharmacist Framework and are structured into five common domains. These are:

  • Person-centred care and collaboration
  • Professional practice
  • Leadership and management
  • Education
  • Research

These domains reflect the structure of the new General Pharmaceutical Council (GPhC) initial education and training standards and the RPS advanced and consultant level curricula.

The new curriculum encourages a flexible approach towards incorporating independent prescribing content into training programmes and allows both a modular approach aligned to current provision, and a new integrated model.

Pharmacists can work towards the curriculum outcomes by compiling an electronic portfolio to demonstrate their learning in collaboration with an educational supervisor and designated prescribing practitioner. This portfolio will then be assessed by an RPS competency committee.

After completing the assessment successfully, the candidates will be awarded the RPS post-registration foundation pharmacist credential. This will demonstrate the pharmacist has developed the necessary clinical and non-clinical capabilities to progress to RPS advanced practice credentialing pathways.

RPS Director of Education Gail Fleming said: “We see this curriculum as being a bridge that will support new registrants, employers and training providers to plan early post registration development programmes over the next five years.

“I would like to take this opportunity to thank the large numbers of people from across and beyond the profession who have contributed to the production of this curriculum. Together we are pharmacy.”

Principal Lead for Post-registration Foundation programmes in Scotland Fiona McMillan said: "We are absolutely delighted to relaunch the Post-registration Foundation Programme in Scotland, using the RPS UK Curriculum, which builds on the work in Scotland over the past 15 years.

“It is fantastic the new programme includes community pharmacy and allows early career pharmacists in Scotland to participate in a robust and supported training programme for all sectors of practice and allow them to develop as independent prescribers"

NHS Health Education and Improvement Wales Dean Margaret Allan said the RPS post-registration foundation curricula will underpin the Wales new post-registration foundation programme that starts from September 2022.

“The Wales programme will support newly registered pharmacists to achieve all the new initial education and training outcomes including independent prescribing accreditation,” Allan said.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less